PreDxion Bio

PreDxion Bio was founded with a mission to revolutionize rapid diagnostics for infectious diseases, starting with COVID-19. The company focuses on developing scalable, saliva-based antigen tests capable of detecting SARS-CoV-2 in asymptomatic and presymptomatic patients. Their innovative technology leverages semiconductor fabrication processes to produce tens of millions of tests daily, aiming to enhance public health response and enable widespread contact tracing. Originally rooted in critical care diagnostics, PreDxion Bio has expanded its vision to include at-home diagnostic solutions.

Key figures associated with PreDxion Bio include experts in biotechnology and semiconductor manufacturing. The company has garnered attention from notable investors in the healthcare and technology sectors. Among its significant achievements is the development of a rapid, near real-time cytokine detection technology, which laid the groundwork for their COVID-19 diagnostic solutions. PreDxion Bio's impact is marked by its potential to significantly improve disease detection and management, thereby contributing to better-informed public health decisions globally.